PSMA-Targeted Radioligand Therapies in Advanced Prostate Cancer

The rationale behind the use of lutetium-177-PSMA-617, a targeted radioligand therapy, in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.

EP. 1: PSMA as a Biomarker in Advanced Prostate Cancer

July 23rd 2021

Dr Scott T. Tagawa describes what prostate-specific membrane antigen (PSMA) is and explains its evolving role as a diagnostic, prognostic and therapeutic target in patients with advanced prostate cancer.

EP. 2: PSMA PET Imaging in Advanced Prostate Cancer

July 23rd 2021

A discussion on the sensitivity and specificity of an emerging imaging modality, PSMA PET, in advanced prostate cancer.

EP. 3: The VISION Study in Metastatic CRPC

July 23rd 2021

An overview of safety and efficacy data presented at ASCO 2021 from the phase III VISION study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

EP. 4: PSMA-Targeted Radioligand Therapy in Advanced Prostate Cancer

July 30th 2021

Scott T. Tagawa, MD, MS, FACP, reviews implications for treating prostate-specific membrane antigen (PSMA) -positive advanced prostate cancer with lutetium-177–PSMA-617 based on results of the phase III VISION study and additional trials in the pipeline.

EP. 5: Testing for PSMA in Community Settings

July 30th 2021

Scott T. Tagawa, MD, MS, FACP, discusses integration of prostate-specific membrane antigen [PSMA] positron emission tomography [PET] imaging into community practice to help identify potential candidates for PSMA-targeted radioligand therapy.